rs4803217 — IFNL3 3'UTR

3' untranslated region variant in IFNL3 (IL28B) that controls mRNA stability via AU-rich elements and miRNA binding — independently predicts hepatitis C spontaneous clearance and treatment response

See your personal result for IFNL3

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

IFNL3 3'UTR — The mRNA Stability Switch Inside the HCV Immunity Locus

The interferon lambda-3 gene (IFNL3, formerly IL28B) on chromosome 19q13.13 encodes one of the body's most potent antiviral cytokines — a protein that activates interferon-stimulated genes11 interferon-stimulated genes
a battery of antiviral defence proteins triggered by JAK-STAT signalling downstream of interferon receptor binding in hepatocytes and mucosal epithelial cells. While the famous rs12979860 variant (in the neighbouring IFNL4 gene) controls whether an aberrant interferon is made, rs4803217 operates by a completely different mechanism: it controls how much functional IFNL3 mRNA survives in the cell long enough to be translated.

This 3' untranslated region (3'UTR) variant sits in the portion of the IFNL3 transcript that is transcribed but not translated into protein — yet here is where the mRNA's fate is determined. The position rs4803217 occupies overlaps with AU-rich elements (AREs), sequences that recruit mRNA-destabilising proteins, and with binding sites for microRNAs including those induced by the hepatitis C virus itself as part of its immune evasion strategy.

The Mechanism

The C allele (favourable, on the plus strand; described as the G allele in papers using coding-strand notation for the minus-strand IFNL3 gene) creates a stable, well-defined 3'UTR RNA secondary structure22 stable, well-defined 3'UTR RNA secondary structure
as demonstrated by SHAPE-MaP structural probing, the C/G allele adopts a single stable conformation that resists mRNA decay. The A allele (risk, plus strand; T in coding notation) replaces this with multiple dynamic, interconverting conformers — an alteration described as among the largest possible RNA structural changes from a single nucleotide substitution.

The biological consequence plays out at two levels. First, the A allele's disordered structure exposes AU-rich elements, recruiting mRNA-destabilising proteins33 mRNA-destabilising proteins
including members of the ZFP36 tristetraprolin family that bind AREs and accelerate poly-A tail removal and transcript degradation that shorten IFNL3 mRNA half-life. Second, and critically, hepatitis C virus induces specific microRNAs that preferentially suppress the A-allele transcript — a molecular trick that allows HCV to selectively silence the host's interferon response in carriers of the risk genotype. The C allele's stable hairpin structure physically blocks these miRNA binding sites, providing resistance to virus-induced immune suppression.

A third layer of control operates at the reporter gene level: the Roy et al. 2021 study44 Roy et al. 2021 study showed that the A allele significantly reduces IFNL3 expression in reporter assays, and the effect is amplified when combined with the ancestral allele at the nearby rs28416813 variant. IRF7 and NF-κB p65, the master transcription factors for type III interferon induction, regulate the IFNL3 promoter; the 3'UTR variants modulate how efficiently their transcriptional output is converted into stable, translatable mRNA.

The Evidence

The mechanistic foundation was established by McFarland et al. in Nature Immunology in 201455 McFarland et al. in Nature Immunology in 2014, who demonstrated that the favourable IFNL3 genotype escapes mRNA decay mediated by both cellular ARE-binding proteins and HCV-induced microRNAs. This explained how a variant entirely outside the protein-coding sequence could exert such profound effects on antiviral responses.

Clinically, Świątek-Kościelna et al. 201766 Świątek-Kościelna et al. 2017 studied 196 Polish HCV genotype-1 patients receiving pegylated interferon-alpha and ribavirin, finding that rs4803217 was the only independently significant predictor of both SVR (p=0.016) and relapse (p=0.024) in multivariate analysis — outperforming rs12979860, rs8099917, and rs12980275. The C allele dose-effect was highly significant (p<0.0001 for allele association; p=0.002 for relapse dose-response). CC carriers showed substantially higher response rates than CA/AA carriers.

Genotype frequencies in the Polish cohort (European ancestry) were CC: 27.6%, CA: 54.6%, AA: 17.9% — consistent with the 1000 Genomes European A allele frequency of ~30%. Population stratification is extreme for this locus: the A allele reaches ~67% in African populations but only ~8% in East Asian populations (where the C allele is near-universal), paralleling the pattern seen at rs12979860 and reflecting shared evolutionary history of the IFNL3/4 haplotype.

Practical Actions

For carriers of the AA genotype (17–18% of Europeans, up to 45% of people of African ancestry), IFNL3 mRNA levels are reduced by the dual mechanisms of increased ARE-mediated decay and HCV-induced miRNA suppression. In the context of HCV infection, this translates to both lower spontaneous clearance rates and reduced response to interferon-based therapy. With modern DAA therapy, treatment outcomes remain high overall, but rs4803217 genotype (along with rs12979860) is relevant for treatment planning, particularly for decisions about abbreviated versus standard-duration regimens.

For AC carriers (~55% of Europeans), IFNL3 mRNA stability is intermediate — one allele produces stable, decay-resistant mRNA, while the other is subject to enhanced degradation and viral suppression. Response rates are intermediate between CC and AA, and standard rather than abbreviated treatment durations are appropriate where relevant.

Beyond HCV, the IFNL3 locus is an important component of the innate antiviral response at hepatic and mucosal barriers. A allele carriers have a subtly blunted IFNL3 response to any viral infection that triggers the IFN-λ pathway, including hepatitis B, respiratory viruses, and potentially emerging pathogens.

Interactions

rs4803217 is in linkage disequilibrium with rs1297986077 rs12979860
the strongest predictor of HCV clearance, located in IFNL4 intron 1 and with rs809991788 rs8099917
the IFNL3 upstream intergenic variant, primary GWAS signal in Australian/Japanese cohorts. The r² values across these variants are moderate to high but vary by ancestry, meaning they provide partially overlapping but non-identical information. The Świątek-Kościelna finding that rs4803217 retains independent predictive value after controlling for rs12979860 supports the hypothesis that the 3'UTR post-transcriptional mechanism it tags adds a genuinely distinct layer of regulation beyond the IFNL4-mediated effects captured by the intronic variants.

rs4803217 also interacts with the nearby rs2841681399 rs28416813
IFNL3 variant in LD with rs4803217; combined ancestral alleles have strong inhibitory effect on IFNL3 expression — a compound regulatory effect not captured by any single variant alone. These variants should not be summed as independent effects; they tag overlapping aspects of the same IFNL3/4 haplotype regulatory state.

Drug Interactions

peginterferon alfa-2a reduced_efficacy literature
peginterferon alfa-2b reduced_efficacy literature
ribavirin reduced_efficacy literature

Genotype Interpretations

What each possible genotype means for this variant.

CC Stable IFNL3 mRNA Beneficial

Favourable antiviral genotype — stable IFNL3 mRNA resists viral immune evasion

You carry two copies of the C allele (the G allele in coding-strand notation used by most papers). This allele creates a stable 3'UTR RNA secondary structure that resists mRNA decay by AU-rich element-binding proteins and blocks the microRNA binding sites that hepatitis C virus exploits to silence the interferon response. About 28% of people of European descent carry this genotype. If exposed to hepatitis C, your IFNL3 mRNA levels remain high under viral challenge, supporting a robust interferon lambda response and better spontaneous clearance and treatment outcomes.

AC One A Allele Intermediate

Intermediate IFNL3 stability — one allele susceptible to mRNA decay and viral suppression

You carry one C allele and one A allele. Your IFNL3 production is intermediate: the C allele produces stable mRNA that resists viral suppression, but the A allele's transcript is more vulnerable to AU-rich-element-mediated decay and HCV-induced microRNA silencing. About 55% of people of European descent share this genotype. In HCV infection, SVR rates are intermediate between CC and AA, and in multivariate analysis this variant contributes independent predictive value beyond what other IFNL3 locus markers capture.

AA Two A Alleles Reduced

Reduced IFNL3 mRNA stability — most vulnerable to viral immune evasion at this locus

You carry two copies of the A allele (the T allele in coding-strand notation). This allele produces an IFNL3 mRNA with a disordered 3'UTR structure that is preferentially degraded by AU-rich element-binding proteins and, critically, suppressed by microRNAs that the hepatitis C virus itself induces — a molecular immune evasion mechanism. About 17% of people of European ancestry carry this genotype (up to 45% of people of African descent). In the Świątek-Kościelna 2017 study, AA carriers showed the lowest SVR rates and highest relapse rates among HCV genotype-1 patients, and rs4803217 was the only independent predictor of SVR and relapse across the variants tested.